GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:SWOBY) » Definitions » PS Ratio

SWOBY (Swedish Orphan Biovitrum AB) PS Ratio : 4.25 (As of Dec. 15, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Swedish Orphan Biovitrum AB PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Swedish Orphan Biovitrum AB's share price is $15.00. Swedish Orphan Biovitrum AB's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $3.53. Hence, Swedish Orphan Biovitrum AB's PS Ratio for today is 4.25.

Warning Sign:

Swedish Orphan Biovitrum AB stock PS Ratio (=4.32) is close to 3-year high of 4.75

The historical rank and industry rank for Swedish Orphan Biovitrum AB's PS Ratio or its related term are showing as below:

SWOBY' s PS Ratio Range Over the Past 10 Years
Min: 2.69   Med: 4.46   Max: 12.78
Current: 4.32

During the past 13 years, Swedish Orphan Biovitrum AB's highest PS Ratio was 12.78. The lowest was 2.69. And the median was 4.46.

SWOBY's PS Ratio is ranked worse than
70.02% of 974 companies
in the Drug Manufacturers industry
Industry Median: 2.34 vs SWOBY: 4.32

Swedish Orphan Biovitrum AB's Revenue per Sharefor the three months ended in Sep. 2024 was $0.97. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $3.53.

Good Sign:

Swedish Orphan Biovitrum AB has shown predictable revenue and earnings growth.

During the past 12 months, the average Revenue per Share Growth Rate of Swedish Orphan Biovitrum AB was 7.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was 11.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was 13.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was 25.80% per year.

During the past 13 years, Swedish Orphan Biovitrum AB's highest 3-Year average Revenue per Share Growth Rate was 40.90% per year. The lowest was -31.70% per year. And the median was 11.50% per year.

Back to Basics: PS Ratio


Swedish Orphan Biovitrum AB PS Ratio Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB PS Ratio Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.19 3.24 3.54 3.43 3.93

Swedish Orphan Biovitrum AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.29 3.93 3.87 4.09 4.48

Competitive Comparison of Swedish Orphan Biovitrum AB's PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's PS Ratio distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's PS Ratio falls into.



Swedish Orphan Biovitrum AB PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Swedish Orphan Biovitrum AB's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=15.00/3.528
=4.25

Swedish Orphan Biovitrum AB's Share Price of today is $15.00.
Swedish Orphan Biovitrum AB's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.53.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Swedish Orphan Biovitrum AB  (OTCPK:SWOBY) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Swedish Orphan Biovitrum AB PS Ratio Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB Business Description

Traded in Other Exchanges
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).